Merck’s ENFLONSIA Receives ACIP Recommendation for Protecting Infants from Severe RSV
Merck’s ENFLONSIA Receives ACIP Endorsement for RSV Prevention in Infants, Marking a Major Milestone in Pediatric Infectious Disease Prevention U.S. CDC panel backs long-acting monoclonal antibody to protect infants during…
Global Energy Access Improves, But More International Financial Support Needed to Close the Gap
Global Energy Access Expands, But Urgent Financing Needed to Bridge Persistent Gaps and Achieve SDG 7 by 2030 A newly released edition of the Tracking SDG 7: The Energy Progress…
BeOne Medicines Gains CHMP Backing for BRUKINSA Tablet Formulation
BeOne Medicines Receives Positive CHMP Opinion for New Film-Coated Tablet Formulation of BRUKINSA® (zanubrutinib), Paving the Way for European Market Approval BeOne Medicines Ltd. a globally operating oncology-focused biopharmaceutical company,…
Biogen Advances Investigational SMA Therapy to Registrational Trials After Positive Phase 1 Data
Biogen Reports Promising Interim Phase 1 Results for Salanersen in Spinal Muscular Atrophy, Prepares for Registrational Trials Biogen has announced encouraging topline results from its Phase 1 clinical trial evaluating…
Price of World’s First Malaria Vaccine for Children in Endemic Countries Slashed by Over 50%, Now Under $5
Bharat Biotech and GSK Commit to Affordable Access to RTS,S, the World’s First Malaria Vaccine, with Major Price Reduction and Expanded Availability in Africa Bharat Biotech International Limited (BBIL) and…
U.S. FDA Grants Orphan Drug Designation to Riliprubart for Treating Antibody-Mediated Rejection in Solid Organ Transplant Recipients
Sanofi’s Riliprubart Receives U.S. FDA Orphan Drug Designation for Antibody-Mediated Rejection in Solid Organ Transplantation The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to riliprubart,…
Novartis Acquires Regulus Therapeutics, Expanding its RNA-Based Drug Pipeline
Novartis Finalizes Acquisition of Regulus Therapeutics, Strengthening Its Renal Disease Portfolio with Promising ADPKD Therapy Novartis AG, a leading global pharmaceutical company, has officially completed its acquisition of Regulus Therapeutics…
Lilly’s Amyvid Receives FDA Label Revision to Support Alzheimer’s Diagnosis
FDA Approves Label Update for Lilly’s Amyvid, Expanding Its Role in Alzheimer’s Disease Diagnosis and Therapy Guidance In a major development for Alzheimer’s diagnostics, Eli Lilly and Company (NYSE: LLY)…
Revolution Medicines Secures $2B Funding from Royalty Pharma for RAS(ON) Cancer Drug Development
Revolution Medicines Secures $2 Billion Strategic Funding from Royalty Pharma to Accelerate Development and Global Commercialization of RAS(ON) Inhibitor Portfolio Revolution Medicines, a leading late-stage oncology company focused on precision…
Bio-Techne Joins Forces with USP to Speed Up Development of mAbs and Gene Therapies
Bio-Techne and USP Forge Strategic Alliance to Advance Quality Standards in Monoclonal Antibody and Gene Therapy Development Bio-Techne Corporation, a global life sciences company renowned for its high-performance reagents, instruments,…
Royalty Pharma and Revolution Medicines Sign Funding Deals Worth Up to $2 Billion
Royalty Pharma and Revolution Medicines Forge $2 Billion Strategic Funding Pact to Accelerate Global Development of RAS Cancer Therapies Royalty Pharma plc, a prominent funder of innovation in the biopharmaceutical…
Baxter Releases Annual Corporate Responsibility Report Highlighting Global Impact
Baxter Releases 2024 Corporate Responsibility Report, Underscoring Sustainability, Stakeholder Engagement, and Global Impact Baxter International,a global leader in medical technology, has published its 2024 Corporate Responsibility Report, reaffirming the company’s…